Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) Receivables (2022 - 2025)

60 Degrees Pharmaceuticals (SXTP) has disclosed Receivables for 4 consecutive years, with $674036.0 as the latest value for Q3 2025.

  • On a quarterly basis, Receivables rose 108.15% to $674036.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $674036.0, a 108.15% increase, with the full-year FY2024 number at $486748.0, up 110.41% from a year prior.
  • Receivables was $674036.0 for Q3 2025 at 60 Degrees Pharmaceuticals, up from $295034.0 in the prior quarter.
  • In the past five years, Receivables ranged from a high of $674036.0 in Q3 2025 to a low of $45965.0 in Q4 2022.
  • A 4-year average of $311022.6 and a median of $296370.0 in 2024 define the central range for Receivables.
  • Peak YoY movement for Receivables: soared 403.28% in 2023, then dropped 0.45% in 2025.
  • 60 Degrees Pharmaceuticals' Receivables stood at $45965.0 in 2022, then skyrocketed by 403.28% to $231332.0 in 2023, then soared by 110.41% to $486748.0 in 2024, then surged by 38.48% to $674036.0 in 2025.
  • Per Business Quant, the three most recent readings for SXTP's Receivables are $674036.0 (Q3 2025), $295034.0 (Q2 2025), and $488243.0 (Q1 2025).